A Phase 3, Randomized, Open-label Trial of Trastuzumab Deruxtecan with Pembrolizumab vs Platinum-based Chemotherapy with Pembrolizumab as First-line Therapy in HER2-overexpressing, PD-L1 TPS <50% Non-squamous NSCLC (DESTINY-Lung06)